1448321-08-1

Upstream product

• 161562-67-0 (2-prop-2-enoxyphenyl)methanamine 
• 207857-15-6 1,3-di(tert-butyloxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine 
• 332882-82-3 1,3-bis(t-butoxycarbonyl)guanidine 
• 1448320-93-1 tert-butyl N-[[(2-methylpropan-2-yl)oxycarbonylamino]-[(2-propoxyphenyl)methylamino]methyl]carbamate 
• 1448321-06-9 benzyl N-[8-(prop-2-enylamino)octyl]carbamate 
• 23434-40-4 8-(benzyloxycarbonylamino)octanoic acid 
• 1448321-04-7 benzyl N-[8-oxo-8-(prop-2-enylamino)octyl]carbamate 
• 160350-20-9 2-allylbenzaldehyde oxime 
• 1002-57-9 8-Aminooctanoic acid 
• 28752-82-1 2-(allyloxy)benzaldehyde 
• 16198-35-9 N-[(2-prop-2-enoxyphenyl)methylidene]hydroxylamine 
• 90-02-8 salicylaldehyde 
• 501-53-1 benzyl chloroformate 

Downstream Products

• 1448321-16-1 benzyl N-[8-[4-[(2-methylpropan-2-yl)oxycarbonylimino]-6-oxo-12-oxa-3,5,7-triazabicyclo[11,4,0]heptadeca-1⁽¹³⁾,9,14,16-tetraen-7-yl]octyl]carbamate 

Relevant academic research and scientific papers

NEW MACROCYCLIC AMIDINOUREA DERIVATIVES, METHODS OF PREPARATION AND USES THEREOF AS CHITINASE INHIBITORS

The present invention relates to macrocyclic amidinourea derivatives of formula 8, methods of preparation and uses thereof, pharmaceutical compositions in particular to be used as chitinase inhibitors in the treatment of a fungal infection.

Novel macrocyclic amidinoureas: Potent non-azole antifungals active against wild-type and resistant Candida species

Novel macrocyclic amidinourea derivatives 11, 18, and 25 were synthesized and evaluated as antifungal agents against wild-type and fluconazole resistant Candida species. Macrocyclic compounds 11 and 18 were synthesized through a convergent approach using as a key step a ring-closing metathesis macrocyclization reaction, whereas compounds 25 were obtained by our previously reported synthetic pathway. All the macrocyclic amidinoureas showed antifungal activity toward different Candida species higher or comparable to fluconazole and resulted highly active against fluconazole resistant Candida strains showing in many cases minimum inhibitory concentration values lower than voriconazole.